Davis Selected Advisers Sells 1,267,195 Shares of Humana Inc. $HUM

Davis Selected Advisers cut its holdings in Humana Inc. (NYSE:HUM) by 76.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 385,539 shares of the insurance provider’s stock after selling 1,267,195 shares during the period. Davis Selected Advisers’ holdings in Humana were worth $100,306,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. AIA Group Ltd purchased a new position in shares of Humana in the third quarter worth $259,000. FNY Investment Advisers LLC grew its stake in Humana by 100.0% during the third quarter. FNY Investment Advisers LLC now owns 1,000 shares of the insurance provider’s stock valued at $260,000 after acquiring an additional 500 shares in the last quarter. Allworth Financial LP grew its stake in Humana by 7.8% during the third quarter. Allworth Financial LP now owns 1,724 shares of the insurance provider’s stock valued at $449,000 after acquiring an additional 125 shares in the last quarter. Swiss Life Asset Management Ltd increased its holdings in Humana by 18.2% in the 3rd quarter. Swiss Life Asset Management Ltd now owns 18,594 shares of the insurance provider’s stock valued at $4,838,000 after acquiring an additional 2,869 shares during the last quarter. Finally, Keyes Stange & Wooten Wealth Management LLC purchased a new stake in Humana in the 3rd quarter worth $201,000. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Performance

Humana stock opened at $170.54 on Thursday. The company’s 50-day moving average price is $206.51 and its 200-day moving average price is $245.16. Humana Inc. has a twelve month low of $163.60 and a twelve month high of $315.35. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 0.70. The company has a market cap of $20.47 billion, a PE ratio of 17.37, a price-to-earnings-growth ratio of 1.83 and a beta of 0.44.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. The firm had revenue of $32.64 billion during the quarter, compared to the consensus estimate of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($2.16) EPS. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, equities research analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Stockholders of record on Friday, March 27th will be issued a $0.885 dividend. The ex-dividend date is Friday, March 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 2.1%. Humana’s payout ratio is 36.05%.

Insider Activity at Humana

In related news, insider Sanjay K. Shetty bought 810 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were purchased at an average price of $185.21 per share, with a total value of $150,020.10. Following the transaction, the insider owned 11,657 shares in the company, valued at $2,158,992.97. This trade represents a 7.47% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on HUM shares. KeyCorp reissued a “sector weight” rating on shares of Humana in a report on Friday, December 12th. Guggenheim reduced their target price on Humana from $312.00 to $252.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Morgan Stanley set a $146.00 price target on Humana in a research note on Thursday, February 12th. Raymond James Financial cut their price target on Humana from $340.00 to $230.00 and set an “outperform” rating for the company in a report on Friday, February 13th. Finally, Robert W. Baird reduced their price objective on Humana from $280.00 to $264.00 and set a “neutral” rating on the stock in a research note on Thursday, December 11th. Seven analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $225.48.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.